XW-014 is under clinical development by Sciwind Biosciences and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase I drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XW-014’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

XW-014 overview

XW-014 is under development for the treatment of non-alcoholic steatohepatitis (NASH), obesity and  type 2 diabetes. The drug candidate acts by targeting glucagon like peptide 1 receptor (GLP1R). It is administered through oral route.

Sciwind Biosciences overview

Sciwind Biosciences (Sciwind) is a clinical-stage biopharmaceutical company. It focuses on the discovery and development of monotherapy and combination treatments to treat metabolic diseases. The company’s product pipeline includes XW003, injectable GLP-1 analogs; XW004, an oral formulation of GLP-1 peptide; XW014, A GLP-1R agonist; and XW003 and XW0017, a GLP-1 and GIP combination for the treatment of diabetes, obesity, and non-alcoholic steatohepatitis (NASH). Sciwind is also investigating XW010, XW013, and XW015 drug programs for undisclosed targets. The company operates a research and development center in Beijing, China. It has a presence in China and the US. Sciwind is headquartered in Hangzhou, Zhejiang, China.

For a complete picture of XW-014’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.